Haemonetics (HAE) Upgraded at Raymond James Financial

Raymond James Financial upgraded shares of Haemonetics (NYSE:HAE) from an underperform rating to a market perform rating in a research note issued to investors on Tuesday.

Several other brokerages have also issued reports on HAE. Morgan Stanley raised Haemonetics from an equal weight rating to an overweight rating and set a $51.00 price target on the stock in a research note on Tuesday. Zacks Investment Research lowered Haemonetics from a buy rating to a hold rating in a research note on Monday, November 20th. Craig Hallum reissued a hold rating and issued a $50.00 price target (up from $40.00) on shares of Haemonetics in a research note on Wednesday, November 8th. Finally, Barrington Research boosted their price target on Haemonetics from $48.00 to $57.00 and gave the company an outperform rating in a research note on Wednesday, November 8th. One analyst has rated the stock with a sell rating, three have assigned a hold rating and four have assigned a buy rating to the stock. The company currently has a consensus rating of Hold and an average target price of $53.33.

Shares of Haemonetics (NYSE:HAE) traded down $0.87 during mid-day trading on Tuesday, reaching $61.76. The company had a trading volume of 428,000 shares, compared to its average volume of 751,933. Haemonetics has a 1-year low of $36.44 and a 1-year high of $63.90. The company has a market capitalization of $3,280.00, a PE ratio of 882.29, a PEG ratio of 4.71 and a beta of 0.99. The company has a debt-to-equity ratio of 0.22, a current ratio of 2.17 and a quick ratio of 1.51.

Haemonetics (NYSE:HAE) last announced its earnings results on Tuesday, November 7th. The medical instruments supplier reported $0.48 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.41 by $0.07. Haemonetics had a return on equity of 11.16% and a net margin of 0.50%. The business had revenue of $225.40 million for the quarter, compared to analysts’ expectations of $219.12 million. During the same period in the prior year, the business posted $0.38 earnings per share. The firm’s revenue was up 2.3% on a year-over-year basis. sell-side analysts predict that Haemonetics will post 1.7 earnings per share for the current year.

In other Haemonetics news, CAO Dan Goldstein sold 4,691 shares of the business’s stock in a transaction that occurred on Monday, November 13th. The stock was sold at an average price of $54.93, for a total value of $257,676.63. Following the transaction, the chief accounting officer now directly owns 3,747 shares of the company’s stock, valued at $205,822.71. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, Director Susan Bartlett Foote sold 16,926 shares of the business’s stock in a transaction that occurred on Friday, November 10th. The shares were sold at an average price of $54.19, for a total value of $917,219.94. Following the completion of the transaction, the director now directly owns 27,313 shares in the company, valued at $1,480,091.47. The disclosure for this sale can be found here. Over the last three months, insiders sold 54,486 shares of company stock worth $3,050,827. Insiders own 1.20% of the company’s stock.

Several large investors have recently modified their holdings of the company. GSA Capital Partners LLP raised its position in shares of Haemonetics by 377.6% during the third quarter. GSA Capital Partners LLP now owns 44,210 shares of the medical instruments supplier’s stock worth $1,984,000 after purchasing an additional 34,953 shares during the period. Neuberger Berman Group LLC raised its position in shares of Haemonetics by 10.2% during the third quarter. Neuberger Berman Group LLC now owns 2,053,458 shares of the medical instruments supplier’s stock worth $92,139,000 after purchasing an additional 189,797 shares during the period. California Public Employees Retirement System raised its position in shares of Haemonetics by 9.2% during the third quarter. California Public Employees Retirement System now owns 100,558 shares of the medical instruments supplier’s stock worth $4,512,000 after purchasing an additional 8,458 shares during the period. Janney Montgomery Scott LLC raised its position in shares of Haemonetics by 3.8% during the third quarter. Janney Montgomery Scott LLC now owns 51,256 shares of the medical instruments supplier’s stock worth $2,300,000 after purchasing an additional 1,879 shares during the period. Finally, Cubist Systematic Strategies LLC raised its position in shares of Haemonetics by 31.6% during the third quarter. Cubist Systematic Strategies LLC now owns 8,677 shares of the medical instruments supplier’s stock worth $389,000 after purchasing an additional 2,082 shares during the period.

TRADEMARK VIOLATION WARNING: “Haemonetics (HAE) Upgraded at Raymond James Financial” was originally posted by Transcript Daily and is the sole property of of Transcript Daily. If you are accessing this piece of content on another site, it was copied illegally and reposted in violation of U.S. and international copyright and trademark laws. The correct version of this piece of content can be viewed at https://transcriptdaily.com/2018/01/05/haemonetics-hae-upgraded-at-raymond-james-financial.html.

Haemonetics Company Profile

Haemonetics Corporation (Haemonetics) is a healthcare company. The Company provides various products to customers involved in the processing, handling and analysis of blood. The Company’s segments include Japan, EMEA, North America Plasma and All Other. Haemonetics provides plasma collection systems and software, which enable plasma fractionators to make pharmaceuticals.

Analyst Recommendations for Haemonetics (NYSE:HAE)

Receive News & Ratings for Haemonetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Haemonetics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply